Dyne Therapeutics Inc. Common Stock vs Old Dominion Freight Line Inc — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.81B), while Old Dominion Freight Line Inc trades at $184.8 (market cap $38.23B). The key difference: Old Dominion Freight Line Inc is far larger — about 13.6× Dyne Therapeutics Inc. Common Stock's market cap, and Old Dominion Freight Line Inc pays a 0.63% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Old Dominion Freight Line Inc for 77 Days on average.
| DYN | ODFL | |
|---|---|---|
Market Cap | $2.81B | $38.23B |
Volume | 2,195,902 | 1,911,209 |
Sector | Health | Industrials |
52-Week High | $26.78 | $248.73 |
52-Week Low | $14.60 | $126.29 |
Typical Hold Time | 0 Days | 77 Days |
Enterprise Value | $2.13B | $37.97B |
Dividend Yield | — | 0.63% |
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
ODFL trades at $183.17, up 0.69% today, with a bearish technical signal but strong fundamentals including a 19.44% net income margin and consistent earnings beats. The company recently announced a 4.9% general rate increase effective October 5, 2026, to offset rising costs. Cash flow trends show positive net cash flow in 2025 and 2026, while the balance sheet reflects low debt levels with a debt-to-asset ratio of 0.73 in 2025.
The stock presents a mixed outlook: analyst consensus is a buy with a $230.93 price target, implying significant upside, but near-term technical resistance and valuation multiples above industry averages pose risks. Key opportunities include operational efficiency and pricing power, while risks involve competitive pressures and economic sensitivity.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →Old Dominion Freight Line is the fourth-largest less-than-truckload carrier in the United States, with more than 240 service centers and 9,200-plus tractors. OD is by far one of the most disciplined and efficient providers in the trucking industry, and its profitability and capital returns stand head and shoulders above its peers. Strategic initiatives revolve around increasing network density through market share gains and maintaining industry-leading service via consistent infrastructure investment.
Read more on ODFL →